- Objective Response Rate among Patients with Locally Advanced or Metastatic Sarcoma Treated with Talimogene Laherparepvec in Combination with Pembrolizumab: A Phase 2 Clinical Trial. JAMA oncology. 2020 Academic Article GET IT
- Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance (Nature Immunology, (2019), 20, 9, (1231-1243), 10.1038/s41590-019-0441-y). Nature Immunology. 2019 Article GET IT
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.
Times cited: 4
Rational design of anti-GITR-based combination immunotherapy.
Times cited: 12
Tumor exosomes induce tunneling nanotubes in lipid raft-enriched regions of human mesothelioma cells.
Experimental Cell Research.
Times cited: 41